Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Tyson Foods, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Tyson Foods, Inc. trades at $54.76 (market cap $18.92B). The key difference: Tyson Foods, Inc. is far larger — about 6.6× Dyne Therapeutics Inc. Common Stock's market cap, and Tyson Foods, Inc. pays a 3.79% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Tyson Foods, Inc. for 77 Days on average.
| DYN | TSN | |
|---|---|---|
Market Cap | $2.86B | $18.92B |
Volume | 3,341,579 | 2,968,585 |
Sector | Health | Consumer Staples |
52-Week High | $26.78 | $68.75 |
52-Week Low | $14.60 | $50.47 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $2.18B | $26.19B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Tyson Foods (TSN) trades at $54.22, up 1.21% with a bullish technical signal despite recent volatility. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining a 53% analyst buy rating. Current valuation metrics include a P/E of 33.2 and P/S of 0.34, with revenue growth projected to $55.7B in 2026. Recent corporate actions include consistent dividend payments of $0.51 per share.
Outlook remains cautiously optimistic with a $65.40 consensus price target representing 21% upside potential. Key risks include ongoing beef segment losses, securities investigations, and margin pressure. The company's ability to maintain dividends while addressing operational challenges will be critical for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
